Understanding Kyprolis® (carfilzomib) for Injection

Kyprolis® (carfilzomib) is the second FDA-approved drug in a class of drugs called proteasome inhibitors, which block the activity of enzyme complexes called proteasomes. Proteasomes carry out the breakdown of proteins in a cell, a process that is necessary for the control of many critical cellular functions.

Update 4/22/2021


Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.